How is Glioblastoma graded and what does the grade mean

Understanding Glioblastoma Grading

Glioblastoma is classified as a Grade IV (4) brain tumor, which is the highest grade in the standard tumor grading system. Let me explain what this means and how the grading system works.

The WHO Grading System

Brain tumors are graded on a scale of I to IV based on how the cancer cells look under a microscope and how quickly they're likely to grow:

• Grade I: Slow-growing, least aggressive
• Grade II: Slow-growing but with some abnormal features
• Grade III: Faster-growing, more aggressive
• Grade IV: Fastest-growing, most aggressive (this is glioblastoma)

What Grade IV Means for Glioblastoma

When your tumor is classified as Grade IV, it tells your medical team several important things:

Cell Appearance: The cancer cells look very abnormal under the microscope, with irregular shapes and sizes. This abnormal appearance is a sign of aggressive behavior.

Growth Rate: Grade IV tumors grow and spread quickly. This is why glioblastoma requires prompt treatment after diagnosis.

Biological Behavior: The tumor cells have characteristics that make them more likely to:

• Invade surrounding healthy brain tissue
• Resist treatment
• Return after initial therapy

Why Grading Matters

The grade helps your oncology team:

• Determine how urgently treatment needs to start
• Select the most appropriate treatment approaches
• Understand what to expect in terms of disease progression
• Plan follow-up monitoring schedules

Additional Classification Information

Beyond the basic Grade IV designation, your doctors may also describe your glioblastoma using other characteristics:

• MGMT methylation status: Whether a specific gene has a chemical modification that affects how the tumor responds to chemotherapy
• IDH mutation status: Whether certain genetic mutations are present, which can influence prognosis and treatment options
• Extent of resection: How much tumor was surgically removed, which affects outcomes

According to the CancerPatientLab webinar on personalized T-cell treatment for glioblastoma, current clinical trials are specifically focusing on newly diagnosed MGMT-negative patients with minimal residual disease (meaning very little tumor remaining after surgery), as these patients tend to have better outcomes with certain immunotherapy approaches.

Questions to Ask Your Healthcare Team

To better understand your specific situation:

1. Beyond Grade IV, what other characteristics does my tumor have? (MGMT status, IDH status, etc.)
2. How much of my tumor was removed during surgery, and does that affect my treatment options?
3. Based on my tumor's grade and characteristics, what treatment approach do you recommend?
4. What does the grade tell us about how quickly this tumor is likely to progress?
5. Are there clinical trials available that match my tumor's specific characteristics?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.